Interpretation of ceritinib clinical trial results and future combination therapy strategies for ALK-rearranged NSCLC

Collin M. Blakely, Jonathan W. Riess

Research output: Contribution to journalReview article

Abstract

Introduction: Lung cancer is the leading cause of cancer-related deaths, with non-small cell lung cancer (NSCLC) accounting for approximately 85% of all lung cancer cases. The continued advancement of DNA sequencing technology and the discovery of multiple specific driver mutations underlying many cases of NSCLC are moving clinical intervention toward a more targeted approach. Here we focus on anaplastic lymphoma kinase (ALK), a member of the receptor tyrosine kinase family, as an oncogenic driver in NSCLC. The ALK gene is rearranged in 3–7% of NSCLCs, and targeted inhibition of ALK is a viable therapy option. Areas covered: We discuss the available treatment options for ALK-positive NSCLC with an emphasis on the second-generation ALK inhibitor ceritinib. We also discuss practical treatment strategies and possible strategies to overcome or delay resistance to ALK inhibitors. Expert opinion: With a robust treatment armamentarium for patients with ALK-positive NSCLC, emphasis has shifted to optimizing individualized treatment strategies to further enhance outcomes for these patients.

Original languageEnglish (US)
Pages (from-to)1061-1075
Number of pages15
JournalExpert Review of Anticancer Therapy
Volume19
Issue number12
DOIs
StatePublished - Dec 2 2019

Keywords

  • ALK
  • ceritinib
  • non-small cell lung cancer
  • resistance

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Interpretation of ceritinib clinical trial results and future combination therapy strategies for ALK-rearranged NSCLC'. Together they form a unique fingerprint.

  • Cite this